The development of targeted therapies has also been followed by resistance, reminiscent of an evolutionary arms race, as exemplified by imatinib and other BCR-ABL inhibitors for the treatment of chronic myelogenous leukaemia. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.